Griffin Securities, Inc. Announces Investment Opinion on Synthetic Biologics, Inc.

NOTE TO EDITORS: The following is an investment opinion issued by Griffin Securities, Inc.

NEW YORK--()--Griffin Securities, Inc. has initiated research coverage on Synthetic Biologics, Inc. (NYSE MKT: SYN) with a Buy Rating and a 12-month target price of $4.00 per share.

Synthetic Biologics, Inc. is a biotechnology company focused on the development of innovative medicines for infectious diseases. The Company has an exclusive channel collaboration with Intrexon Corporation, a biotechnology company focused on the industrial engineering of synthetic biology, to develop monoclonal antibody-based therapies for infectious diseases, including Acinetobacter baumannii and Bordetella pertussis infections, and a clinical program for the prevention of Clostridium difficile infection. In addition, the Company has an oral therapy for relapsing-remitting multiple sclerosis in clinical development. For a copy of the report, including disclosures, click here: http://griffinsecurities.com/upload/reports/Griffin_SYN_Initiation_Report_05Feb13.pdf

Griffin Securities, Inc. is a member of the Financial Industry Regulatory Authority (FINRA Broker ID 43229) and the Securities Investor Protection Corporation.

Contacts

Griffin Securities, Inc.
Keith Markey, Ph.D., M.B.A., 212-509-9500 (x7914)
www.griffinsecurities.com

Sharing

Contacts

Griffin Securities, Inc.
Keith Markey, Ph.D., M.B.A., 212-509-9500 (x7914)
www.griffinsecurities.com